| Bioactivity | Eluvixtamab (AMG-330) is an anti-CD33 bispecific T-cell engager. AMG 330 recognizes a linear epitope located in the V-set domain of CD33 with the core sequence IPYYDKN. Eluvixtamab binds CD33 on AML cells and CD3 on T cells, facilitating T-cell destruction of CD33+ cells[1]. |
| CAS | 1679391-73-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Friedrich M, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57. |